Excelimmune Inc. announced Tuesday it has closed its Series B financing at $10.5 million – funding that will be used to advance the company’s drug candidate to treat methicillin-resistant Staphylococcus aureus (MRSA).

The Woburn-based company said the funding comes from “a syndicate of new and existing high net worth individual investors,” who were not named.

SOURCE